FAST Roadmap to a C.U.R.E. 2.0
Join Allyson Berent at the 2022 FAST Science Summit as she discusses the roadmap to a C.U.R.E. 2.0 for Angelman Syndrome and the science behind it. Be part of the movement!
FAST Global Search & Rescue Initiative: Finding Every Individual Globally Living with Angelman Syndrome and Why it Matters
Discover the FAST Global Search & Rescue Initiative’s mission to identify every individual with Angelman syndrome worldwide. Learn about the importance, challenges, and how to get involved.
Development and Validation of a Newborn Screening Test for Angelman Syndrome
Explore the development and validation of a newborn screening test for Angelman Syndrome with Dr. Mei Baker. Learn about the integration process, follow-up care, and ethical considerations.
Crowd-Sourcing Research into Nonepileptic Myoclunus in Angelman Syndrome
Explore Dr. Carson’s research on non-epileptic myoclonus in Angelman syndrome, highlighting the importance of understanding this condition, challenges in diagnosis, and potential treatments.
Clinical Trial Basics: What Parents Need to Know About Trial Participation
Explore the basics of clinical trials for parents considering participation for their children with Angelman Syndrome. Understand the phases, control groups, consent process, and how to make an informed decision.
Breaking the Mold: How Patient Groups like FAST are Reshaping Drug Development in Rare Disease
Explore how patient groups like FAST are revolutionizing drug development in rare diseases. Discover the importance of prevalence, progress, pathways, and partnerships in this process.
Angelman Syndrome Biomarker and Outcome Measure Consortium: What’s the Hype? Why Does it Matter So Much?
Explore the Angelman Syndrome Biomarker and Outcome Measure Consortium’s efforts to improve lives through the development of biomarkers and outcome measures for this rare neurodevelopmental disorder.
An Update on HALOS Clinical Trial in Individuals with Angelman Syndrome
Explore the latest updates on the HALOS clinical trial for Angelman syndrome by Ionis Pharmaceuticals. Learn about the development of ION582 and its potential to treat this condition.
Advancing Human Stem Cell-Derived Platforms for Angelman Syndrome Research
Explore the advancements in Angelman Syndrome research through human stem cell-derived platforms. Discover diverse models, cerebral organoids studies, and high-throughput drug testing methods.
A Family-Centered Approach to Measuring Communication Ability within Clinical Trials
Explore Dr. Christie Zigler’s development of the ORCA measure, a unique tool for evaluating communication ability in clinical trials, specifically for Angelman Syndrome. Learn about its creation, validation, and future plans.